Disclosed are immunogenic variants of the ligand for Receptor activator of nuclear factor-kappa B ligand (RANKL), which include a number of mutations which reduce binding to RANK. The immunogenic variants further include at least one foreign T-helper epitope. Also disclosed are nucleic acid fragments encoding the variants as are vectors and transformed cells. Further, novel adjuvant combinations between at least one micelle-forming adjuvant and one further non-micelle forming adjuvant are also disclosed.
